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Background: Radium-223 dichloride (radium-223), a ﬁrst-in-class α-emitting radiopharmaceutical, is recommended in
both pre- and post-docetaxel settings in patients with castration-resistant prostate cancer (CRPC) and symptomatic
bone metastases based on overall survival beneﬁt demonstrated in the phase III ALSYMPCA study. ALSYMPCA included
prospective measurements of health-related quality of life (QOL) using two validated instruments: the general EuroQoL 5D
(EQ-5D) and the disease-speciﬁc Functional Assessment of Cancer Therapy-Prostate (FACT-P).
Patients and methods: Analyses were conducted to determine treatment effects of radium-223 plus standard of
care (SOC) versus placebo plus SOC on QOL using FACT-P and EQ-5D. Outcomes assessed were percentage of
patients experiencing improvement, percentage of patients experiencing worsening, and mean QOL scores during
the study.
Results: Analyses were carried out on the intent-to-treat population of patients randomized to receive radium-223 (n
= 614) or placebo (n = 307). The mean baseline EQ-5D utility and FACT-P total scores were similar between treatment
groups. A signiﬁcantly higher percentage of patients receiving radium-223 experienced meaningful improvement in
EQ-5D utility score on treatment versus placebo {29.2% versus 18.5%, respectively; P = 0.004; odds ratio (OR) = 1.82
[95% conﬁdence interval (CI) 1.21–2.74]}. Findings were similar for FACT-P total score [24.6% versus 16.1%, respect-
ively; P = 0.020; OR = 1.70 (95% CI 1.08–2.65)]. A lower percentage of patients receiving radium-223 experienced
meaningful worsening versus placebo measured by EQ-5D utility score and FACT-P total score. Prior docetaxel use
and current bisphosphonate use did not affect these ﬁndings. Treatment was a signiﬁcant predictor of EQ-5D utility
score, with radium-223 associated with higher scores versus placebo (0.56 versus 0.50, respectively; P = 0.002).
Findings were similar for FACT-P total score (99.08 versus 95.22, respectively; P = 0.004).
Conclusions: QOL data from ALSYMPCA demonstrated that improved survival with radium-223 is accompanied by
signiﬁcant QOL beneﬁts, including a higher percentage of patients with meaningful QOL improvement and a slower
decline in QOL over time in patients with CRPC.
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introduction
Patients with castration-resistant prostate cancer (CRPC) and
bone metastases often present with symptoms such as pain,
fatigue, anorexia, and, rarely, spinal cord compression, contribut-
ing to rapid and signiﬁcant deterioration in health-related quality
of life (QOL) and mortality [1–4]. Radium-223 dichloride
(radium-223), a ﬁrst-in-class α-emitting radiopharmaceutical,
has demonstrated overall survival (OS) beneﬁt in patients with
CRPC and symptomatic bone metastases and no visceral metasta-
ses. Clinical practice guidelines recommend radium-223 in both
pre- and post-docetaxel settings [5, 6]. Radium-223 approval was
based on results from ALSYMPCA, a phase III, randomized,
double-blind, placebo-controlled trial. In ALSYMPCA, radium-
223 versus placebo prolonged OS by 3.6 months [hazard ratio
(HR) 0.70; 95% conﬁdence interval (CI) 0.58–0.83] and pro-
longed time to ﬁrst symptomatic skeletal event (SSE) by 5.8
months (HR 0.66; 95% CI 0.52–0.83) [7, 8]. Radium-223 was
associated with positive effects on QOL and a favorable safety
proﬁle with a low myelosuppression incidence [9–12].
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Clinical practice guidelines recognize radium-223 as having an
OS beneﬁt and preserving QOL [5, 6, 13, 14]. The ALSYMPCA
design included prospective QOL measurements using two vali-
dated instruments: EuroQoL EQ-5D, designed for the general
population, and Functional Assessment of Cancer Therapy-
Prostate (FACT-P), a disease-speciﬁc questionnaire for patients
with prostate cancer [15, 16].
The goal of this ALSYMPCA data analysis was to determine
effects of radium-223 plus standard of care (SOC) versus placebo
plus SOC on the percentage of patients experiencing improvement
or worsening in QOL while on treatment and observed over time.
methods
ALSYMPCA was a multicenter trial conducted at 136 sites (NCT00699751).
Detailed methodology was reported elsewhere [7]. The primary end point
was OS; QOL was a secondary clinical beneﬁt end point. Descriptions of
study conduct, patients, and treatment regimens are in Supplementary
Materials, available at Annals of Oncology online.
health-related QOL assessments
QOL was assessed using EQ-5D [17] and FACT-P [15] questionnaires, completed
by patients at randomization, on treatment at weeks 16 and 24, and at study dis-
continuation. During the ﬁrst 28 weeks of follow-up, EQ-5D was completed every
2 months, and FACT-P was administered once at week 44 (22 weeks after last
study drug administration). During the remaining follow-up period, EQ-5D was
completed every 4 months, 6 times in total (although because of death and loss to
follow-up, no EQ-5D data were collected at the 148-week visit).
The EQ-5D comprises ﬁve ordinal categorical responses (mobility, self-
care, usual activities, pain/discomfort, and anxiety/depression) used to deter-
mine a country-speciﬁc utility score, a higher score indicating better QOL
[17]. This analysis used UK tariffs to calculate utility scores.
FACT-P (version 4), a validated 39-item questionnaire, has four subscales
for physical, emotional, functional, and social well-being and one for pros-
tate cancer symptoms (PCS); these constitute a total score, a higher score in-
dicating better QOL. Pain-related questions from the PCS were used to
estimate a pain-related score (PRS) (see Supplementary Materials, available
at Annals of Oncology online).
statistical analyses
Although ALSYMPCA included a pre-planned descriptive comparison of
QOL, all hypothesis-testing analyses reported here were post hoc. Analyses
were carried out on the intent-to-treat population, but limited to patients
with a baseline assessment and ≥1 post-baseline assessment (i.e. weeks 16
and/or 24 or both). Three analyses were conducted using the EQ-5D utility
score (utility score) and FACT-P total score: a responder analysis investigat-
ing treatment effects on percentage of patients experiencing meaningful
QOL improvement on treatment; a similar on-treatment analysis of percent-
age of patients experiencing meaningful QOL worsening; and an overall ana-
lysis (using data collected during treatment and follow-up) investigating
treatment effects on mean QOL and mean change from baseline over time
[18]. For all analyses, when treatment differences were signiﬁcant (P < 0.05)
for FACT-P total score, subscales were evaluated to determine which were
associated with the differences. When a signiﬁcant QOL difference between
treatment groups was found, regression models with docetaxel status (yes/
no) and interaction terms were used to determine whether the treatment
effect was different between pre-docetaxel and post-docetaxel subgroups;
similar models were used to determine whether treatment effect was different
between current bisphosphonate use (yes/no) subgroups [19].
When deﬁning ‘meaningful improvement’ (or ‘meaningful worsening’),
the upper limit of the minimally important difference (MID) range was used
[15, 20, 21, 22], minimizing the likelihood of falsely identifying a patient as
having improvement (or worsening). The utility score MID was 0.1; MIDs
for FACT-P total score and subscales are shown in supplementary Table S1,
available at Annals of Oncology online. χ2 tests were used to test for an as-
sociation between treatment and likelihood of experiencing meaningful
improvement (i.e. responder) or worsening in QOL [19]. Except for PRS,
patients experiencing a QOL increase ≥MID from baseline at week 16
and/or week 24 were considered responders. Conversely, those experiencing
a decrease in QOL score ≥MID from baseline at these time points were con-
sidered to have experienced worsening QOL. For PRS, a responder was
deﬁned as having a score increase of ≥2 without initiating opioid treatment.
A patient initiating opioid use after baseline was assumed to have worsening
pain and therefore to be a non-responder from that time forward.
Mixed-effect analysis of covariance (ANCOVA) regression models assessed
the average treatment effect on utility score and FACT-P total score throughout
the study. Covariates or main effects used were QOL score at baseline and on
treatment at week 16 or 24, total alkaline phosphatase (ALP) concentration
(≥220 or <220 U/l), current bisphosphonate use (yes/no), and prior docetaxel
use (yes/no). Time was a random effect. A linear regression model, with the
same covariates and main effects as the mixed-effect model, was used to
conduct ANCOVA to provide descriptive assessments of treatment effect on
utility score and FACT-P total score and subscales at each assessment time
point. In both models, the dependent variable was mean change in score from
baseline. To obtain estimates of the mean QOL on study, regression models
were also run using mean score as a dependent variable [23].
Missing data were assumed to be missing completely at random for all
analyses; no imputation was done to estimate missing observations. To in-
vestigate potential selection bias due to missing data, pattern-mixture
models were used to re-evaluate the mixed-effect ANCOVA analyses and test
for evidence of differential response based on extent of missing data [24].
The regression model included a variable for extent of missing data (classify-
ing patients as having complete versus incomplete data), and interaction
terms with this variable and each respective covariate. Statistical tests were
conducted to determine whether missing data status was a signiﬁcant pre-
dictor of treatment effect on utility score and FACT-P total score. If so, this
would provide evidence of bias in the mixed-effect ANCOVA analysis.
results
All analyses were carried out on the intent-to-treat population
of 921 patients randomized to receive either radium-223 (n =
614) or placebo (n = 307). At baseline, most patients (>93%)
completed EQ-5D and FACT-P questionnaires. Completion
rates decreased with each subsequent assessment because of
study discontinuation, loss to follow-up, or death, with slightly
higher completion rates in the radium-223 group than in the
placebo group at post-baseline visits (supplementary Table S2,
available at Annals of Oncology online).
responder analysis
A signiﬁcantly higher percentage of patients receiving radium-
223 had improved utility scores on treatment versus placebo
(both with SOC) (29.2% versus 18.5%, respectively; P = 0.004),
corresponding to an odds ratio (OR) of 1.82 (95% CI 1.21–
2.74). Similarly, a signiﬁcantly higher percentage of patients re-
ceiving radium-223 had a meaningful improvement in FACT-P
total score on treatment [24.6% versus 16.1%, respectively;
P = 0.020; OR = 1.70 (95% CI 1.08–2.65)] (Figure 1). Subgroup
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analyses (OR and 95% CI) for all patients and by ALSYMPCA
trial stratiﬁcation factors (baseline ALP, current bisphosphonate
use, and prior docetaxel use) for FACT-P total score, PRS, and
utility score are shown in supplementary Figure S1, available at
Annals of Oncology online.
Analysis of FACT-P subscales indicated that responder rates
for FACT-P total score were driven by improvements in three of
ﬁve subscales (emotional and functional well-being, and PCS),
and one approached signiﬁcance (physical well-being) (Figure 2).
In a more detailed analysis of pain (using PRS), both groups had
a relatively low meaningful improvement in pain (radium-223:
30.2%; placebo: 20.1%; P = 0.010) (Figure 2). Table 1 shows per-
visit details of improvement rates underlying this analysis.
Logistic regression analysis investigating consistency of treat-
ment effect across docetaxel subgroups (pre-docetaxel versus post-
docetaxel) indicated no difference in treatment effect on improve-
ment in utility score (P = 0.178) or FACT-P total score (P = 0.637).
Similar analysis across current bisphosphonate use (yes/no) sub-
groups found no difference in treatment effect on improvement in
utility score (P = 0.977) or FACT-P total score (P = 0.800).
percentage worsening analysis
A lower percentage of patients receiving radium-223 experienced
a meaningful worsening in utility score versus placebo (both with
SOC) [36.0% versus 54.0%, respectively; P < 0.001; OR = 0.48
(95% CI 0.34–0.67)]. For FACT-P total score, the percentage of
patients experiencing meaningful worsening was nominally dif-
ferent [44.3% versus 51.6%, respectively; P = 0.095; OR = 0.75
(95% CI 0.53–1.05)]. Because no signiﬁcant difference was seen
in FACT-P total score, comparisons of treatment effect for sub-
scales and PRS were not investigated. Table 1 shows per-visit
details of worsening rates underlying this analysis.
Logistic regression analysis investigating treatment effect across
docetaxel subgroups (pre-docetaxel versus post-docetaxel) indi-
cated no difference in treatment effect on worsening based on
utility score (P = 0.248) or FACT-P total score (P = 0.698).
Similar analysis across bisphosphonate use (yes/no) subgroups
found no difference in treatment effect on worsening of utility
score (P = 0.069) or FACT-P total score (P = 0.746).
treatment effects on mean QOL score and change
from baseline
The mean baseline utility and FACT-P total scores were similar
between treatment groups. Using all EQ-5D data collected
throughout the study period (on-treatment and follow-up),
treatment was a signiﬁcant predictor of utility score, with
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Figure 1. Percentage of patients experiencing a meaningful improvement
in EQ-5D utility score or FACT-P total score while on treatment (week 16
and/or week 24). EQ-5D, EuroQoL 5D; FACT-P, Functional Assessment of
Cancer Therapy-Prostate. aA responder was deﬁned as a patient having an
increase in FACT-P total score of ≥10 from baseline at either week 16 and/
or week 24. bA responder was deﬁned as a patient having an increase in EQ-
5D utility score of ≥0.1 from baseline at either week 16 and/or week 24.
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Figure 2. Percentage of patients experiencing a meaningful improvement in Functional Assessment of Cancer Therapy-Prostate (FACT-P) subscale scores
while on treatment (week 16 and/or week 24). EWB, emotional well-being; FWB, functional well-being; PCS, prostate cancer subscale; PRS, pain-related score;
PWB, physical well-being; SWB, social/family well-being. aA responder was deﬁned as a patient having an increase in score of ≥3 points from baseline at either
week 16 and/or week 24. bFor the pain-related score of the PCS, a responder was deﬁned as a patient having an increase in score of ≥2 from baseline at either
week 16 and/or week 24. A patient who initiated opioid use after baseline was assumed to be a non-responder from that time point forward.
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radium-223 associated with higher scores versus placebo (0.56
versus 0.50; P = 0.002). The mean change from baseline in
utility score was −0.10 with radium-223 and −0.16 with placebo
(P = 0.002). For FACT-P total score, radium-223 was associated
with a higher score (99.08 versus 95.22; P = 0.004) and a sig-
niﬁcantly smaller decrease from baseline versus placebo (−4.83
versus −8.69; P = 0.004). The mean changes in utility and
FACT-P total scores from baseline over time (Figure 3; supple-
mentary Figure S2, available at Annals of Oncology online shows
changes in FACT-P subscales) indicate that higher QOL
observed with radium-223 patients was a direct consequence of
a slower rate of decline in QOL with radium-223 versus placebo.
Differences in the mean score for radium-223 - placebo for all
patients and by ALSYMPCA trial stratiﬁcation factors (baseline
ALP, current bisphosphonate use, and prior docetaxel use) for
FACT-P total score, PRS, and utility score are shown in supple-
mentary Figure S3, available at Annals of Oncology online.
The mean changes from baseline for each FACT-P subscale
score were signiﬁcantly different, favoring radium-223, for all
except social well-being (Table 2). For PCS, containing items
speciﬁc to prostate cancer, mean change from baseline in scores
was signiﬁcantly greater (indicating improved QOL) with
radium-223 versus placebo (P = 0.009). Analysis of pain-related
and non-pain-related PCS items indicated that treatment effects
on pain were the primary reason for change in overall PCS score
with radium-223 (Table 2).
Mixed-effect regression analysis investigating treatment effect
within pre-docetaxel and post-docetaxel subgroups indicated
no difference in treatment effect on mean change from baseline
in utility (P = 0.714) or FACT-P total score (P = 0.785).
Comparison of subgroups based on current bisphosphonate use
(yes/no) found no difference in treatment effect on FACT-P
total score (P = 0.309), but there was a difference in treatment
effect on utility score (P = 0.034), with patients receiving
bisphosphonates experiencing greater treatment beneﬁt (0.61
versus 0.50, P < 0.001) than patients not currently receiving
bisphosphonates (0.53 versus 0.50, respectively; P = 0.284).
Per-visit descriptive analyses of least-squares mean change from
baseline in utility score and FACT-P total score are in supple-
mentary Tables S3 and S4, respectively, available at Annals of
Oncology online.
discussion
These analyses of ALSYMPCA QOL data consistently showed
treatment beneﬁt with radium-223 plus SOC versus placebo plus
SOC, as measured by utility and FACT-P total scores. In patients
receiving radium-223, a signiﬁcantly higher percentage experi-
enced meaningful improvement in QOL and a lower percentage
experienced meaningful worsening in QOL versus placebo.
Radium-223 treatment appeared to result in higher mean QOL
scores on study versus placebo, a function of slower deterioration
over time. This trend was consistent across four of ﬁve FACT-P
subscales, indicating that treatment effects extend across multiple
QOL domains. Analysis of pain-related and non-pain-related com-
ponents of the PCS suggests that pain reduction primarily contrib-
uted to PCS treatment differences. This effect is consistent with
other ALSYMPCA analyses showing that radium-223 signiﬁcantly
prolonged time to ﬁrst opioid use [11], and that radium-223 was
equally effective, regardless of opioid use at baseline [25]. These
data are consistent with those of an earlier phase II study, showing
pain response (reduced pain and stable analgesic consumption) in
71% of patients with CRPC receiving radium-223 [26].
Treatment effects in utility and FACT-P total scores appeared
consistent across pre-docetaxel and post-docetaxel subgroups,
and except for change from baseline in mean utility score, treat-
ment beneﬁt is consistent across current bisphosphonate use
(yes/no) subgroups.
QOL deterioration over time for CRPC patients is well docu-
mented, and may be a prognostic factor for more rapid disease
progression [1, 2]. Agents such as radium-223 that delay QOL
deterioration or improve overall QOL and OS are valuable addi-
tions to treatment; there is evidence of a durable response to
radium-223 over time, as measured by FACT-P total score and
Table 1. Percentage of patients with a meaningful improvement or meaningful worsening in health-related quality of life as measured by EQ-5D
utility score and FACT-P total score
Meaningful change EQ-5D utility score FACT-P total score
Radium-223, n/N (%) Placebo, n/N (%) Radium-223, n/N (%) Placebo, n/N (%)
Improvementa
Week 16 114/460 (24.8) 28/194 (14.4) 85/407 (20.9) 24/177 (13.6)
Week 24 75/343 (21.9) 20/131 (15.3) 57/314 (18.2) 10/120 (8.3)
Worseningb
Week 16 109/460 (23.7) 76/194 (39.2) 129/407 (31.7) 68/177 (38.4)
Week 24 104/343 (30.3) 59/131 (45.0) 120/314 (38.2) 58/120 (48.3)
Stable
Week 16 237/460 (51.5) 90/194 (46.4) 193/407 (47.4) 85/177 (48.0)
Week 24 164/343 (47.8) 52/131 (39.7) 137/314 (43.6) 52/120 (43.3)
aMeaningful improvement was defined as a ≥0.1 increase in EQ-5D utility score or ≥10 increase in FACT-P total score at either week 16 and/or week 24.
Patients could have improvement or worsening at different visits.
bMeaningful worsening was defined as a ≥0.1 decrease in EQ-5D utility score or ≥10 decrease in FACT-P total score at either week 16 and/or week 24.
Patients could have improvement or worsening at different visits.
EQ-5D, EuroQoL 5D; FACT-P, Functional Assessment of Cancer Therapy-Prostate.
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subscales. Recent analyses of QOL data from enzalutamide and
abiraterone studies in CRPC patients documented the QOL
decline in patients using FACT-P, and reported these agents’
beneﬁcial effects on QOL [27, 28]. However, several confound-
ing factors make comparisons of QOL ﬁndings across these
studies and ALSYMPCA difﬁcult. Post hoc analysis of FACT-P
data from the abiraterone trial, where 48% of patients were clas-
siﬁed as responders, used the same meaningful improvement in
FACT-P total score as the current radium-223 analysis, but the
abiraterone analysis used only data from patients with a low
FACT-P total score at baseline (i.e. those with the greatest
chance for improvement). Furthermore, there were more
FACT-P assessments (at cycles 1, 4, 7, 10, and every 6 cycles
thereafter) than in ALSYMPCA because of longer treatment
duration, giving patients more opportunities to be responders
[28]. In addition, statistical analyses used across studies, and dif-
fering assumptions in each model, make direct comparisons of
QOL ﬁndings challenging.
Limitations of the ALSYMPCA analyses reported here
include the results being from post hoc analyses. However, col-
lection of QOL data in ALSYMPCAwas done prospectively, and
measured using validated QOL instruments, one (FACT-P) spe-
ciﬁc for prostate cancer. If the assumption of data missing com-
pletely at random was not correct, some analyses may be biased.
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However, the pattern-mixture model analysis was done to detect
evidence of informative missing, and no evidence was found.
Decreases in EQ-5D and FACT-P completion rates over time
were a potentially confounding factor, although a pattern-
mixture model showed no evidence that missing data biased the
analyses. Moreover, responder analysis used the upper limit of
the clinically meaningful range for FACT-P subscales to minim-
ize the likelihood of falsely identifying a patient as a responder.
A limitation of the analysis of pain improvement is that once a
patient initiated opioid therapy, signiﬁcant increases or decreases
in pain management could not be accurately assessed. Regarding
multiple testing, a conservative approach using the Bonferroni
correction (α = 0.008) when evaluating the three main analyses
applied to utility and FACT-P total scores would change only
the conclusion regarding FACT-P responder analysis, to non-
signiﬁcant (P = 0.020) after applying the correction. Even with
these conservative approaches, signiﬁcantly more patients re-
ceiving radium-223 experienced a meaningful increase in QOL.
The ﬁndings reported here and in the primary report of
ALSYMPCA [7] suggest that in the clinical practice setting,
radium-223 treatment was associated with both increased survival
outcomes and clinically meaningful improvements in QOL.
Furthermore, pain is often associated with SSEs (e.g. spinal cord
compression) in CRPC patients, and radium-223 demonstrated
an additional clinical beneﬁt of delaying SSE occurrence (by 5.8
months). Analysis of utility scores in ALSYMPCA before/after
SSE and before/after disease progression found that the radium-
223 QOL beneﬁt was greatest in stable disease and pre-SSE set-
tings [29], suggesting that delay to ﬁrst SSE is associated with
better QOL. Overall, interest in monitoring QOL during treat-
ment in patients with CRPC is increasing, and recommenda-
tions have been made to include patient-reported outcomes and
QOL, using instruments such as FACT-P [30]. A recent report
of the European Society for Medical Oncology (ESMO) vali-
dated tool to assess magnitude of clinical beneﬁt scale (ESMO-
MCBS), which assesses QOL and survival, rated radium-223 as
having the highest level of clinical beneﬁt [14]. These QOL
instruments continue to be evaluated and reﬁned in this popula-
tion, especially in conﬁguring questions addressing clinical re-
levance from the oncologist’s perspective and symptoms of
greatest concern to patients [31–34]. Examples of QOL instru-
ments that may provide valuable insights in this CRPC setting
are the EORTC QLQ-BM22 instrument for patients with bone
metastases [35], and the FACT-Bone Pain [36].
In conclusion, analyses of EQ-5D and FACT-P data from
the ALSYMPCA trial demonstrate that improved survival with
radium-223 is accompanied by signiﬁcant QOL beneﬁts, includ-
ing a higher percentage of patients with meaningful improve-
ment in QOL and an overall slower decline in QOL over time.
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Table 2. Mean change from baseline in EQ-5D utility score, FACT-P total score, and pain-related and non-pain-related components of the FACT-P
prostate cancer subscale (PCS) (ANCOVA analysis; entire trial period)
Score Mean score
(radium-223; RA)
Change from baseline
(radium-223; RA)
Mean score
(placebo; PL)
Change from baseline
(placebo; PL)
Difference
(RA−PL)
P-value
(RA–PL)
EQ-5Da
EQ-5D utility score 0.56 −0.10 0.50 −0.16 0.06 0.002
FACT-Pb
FACT-P total score 99.08 −4.83 95.22 −8.69 3.86 0.004
Physical well-being 18.48 −1.59 17.59 −2.49 0.90 0.013
Social/family well-being 20.94 −0.16 20.98 −0.13 −0.04 0.900
Emotional well-being 16.64 −0.28 15.59 −1.33 1.05 <0.001
Functional well-being 15.39 −1.81 14.53 −2.67 0.86 0.017
Prostate cancer score 27.83 −0.82 26.59 −2.07 1.25 0.009
Pain-related scorec 8.38 0.29 7.63 −0.46 0.75 0.006
Non-pain-related component 19.38 −1.11 18.98 −1.51 0.40 0.212
aEQ-5D utility scores were available for 220 radium-223 patients and 84 placebo patients at follow-up visit 2 (week 44).
bFACT-P total scores were available for 186 radium-223 patients and 75 placebo patients at follow-up visit 2 (week 44).
cHigher values for pain-related score indicated reduced pain.
Patient numbers at each visit are shown in supplementary Tables S1 and S2, available at Annals of Oncology online.
ANCOVA, analysis of covariance; EQ-5D, EuroQoL 5D; FACT-P, Functional Assessment of Cancer Therapy-Prostate.
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